ATE429504T1 - Proteinexpressionsvektor und benutzung desselbigen - Google Patents

Proteinexpressionsvektor und benutzung desselbigen

Info

Publication number
ATE429504T1
ATE429504T1 AT99972690T AT99972690T ATE429504T1 AT E429504 T1 ATE429504 T1 AT E429504T1 AT 99972690 T AT99972690 T AT 99972690T AT 99972690 T AT99972690 T AT 99972690T AT E429504 T1 ATE429504 T1 AT E429504T1
Authority
AT
Austria
Prior art keywords
expression vector
nucleotide sequence
protein expression
downstream side
cloning site
Prior art date
Application number
AT99972690T
Other languages
English (en)
Inventor
Hidetoshi Uemura
Akira Okui
Katsuya Kominami
Nozomi - Yamaguchi
Shinichi Mitsui
Original Assignee
Fuso Pharmaceutical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuso Pharmaceutical Ind filed Critical Fuso Pharmaceutical Ind
Application granted granted Critical
Publication of ATE429504T1 publication Critical patent/ATE429504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99972690T 1998-11-20 1999-11-19 Proteinexpressionsvektor und benutzung desselbigen ATE429504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33151598 1998-11-20
PCT/JP1999/006474 WO2000031284A1 (en) 1998-11-20 1999-11-19 Protein expression vector and utilization thereof

Publications (1)

Publication Number Publication Date
ATE429504T1 true ATE429504T1 (de) 2009-05-15

Family

ID=18244518

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972690T ATE429504T1 (de) 1998-11-20 1999-11-19 Proteinexpressionsvektor und benutzung desselbigen

Country Status (8)

Country Link
US (1) US7029909B1 (de)
EP (1) EP1132479B1 (de)
JP (1) JP4475814B2 (de)
AT (1) ATE429504T1 (de)
AU (1) AU765111B2 (de)
CA (1) CA2350226C (de)
DE (1) DE69940785D1 (de)
WO (1) WO2000031284A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061064A2 (de) * 2001-02-01 2002-08-08 Roche Diagnostics Gmbh Verfahren zur herstellung von rekombinantem trypsin
AU2002350039A1 (en) 2001-10-29 2003-05-12 Renovis, Inc. Method for isolating cell-type specific mrnas
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
JP2006345831A (ja) * 2005-06-20 2006-12-28 P-Lap:Kk Ｄｎａ、ベクター、形質転換体、及びａｐａタンパク質の製造方法
JP5130662B2 (ja) * 2006-06-07 2013-01-30 Ｊｎｃ株式会社 タンパク質の可溶性タンパク質としての製造方法
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
EP2162540A2 (de) 2007-05-22 2010-03-17 Amgen Inc. Zusammensetzungen und verfahren zur herstellung biologisch aktiver fusionsproteine
EP3369827B1 (de) 2008-03-12 2020-12-23 The Rockefeller University Verfahren und zusammensetzungen zur translationalen profilierung und molekularen phänotypisierung
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
US20120231006A1 (en) 2009-11-20 2012-09-13 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
AU2011289426A1 (en) 2010-08-10 2013-02-28 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
JP2014507136A (ja) 2011-01-18 2014-03-27 アムジエン・インコーポレーテツド ＮａＶ１．７ノックアウトマウスとそれらの使用
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
AU2013222188A1 (en) 2012-02-22 2014-09-11 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
WO2013177533A1 (en) * 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
WO2015031686A1 (en) 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
EP3155003B9 (de) 2014-06-13 2020-12-30 Whitehead Institute for Biomedical Research Amyloid-beta-expression-konstrukte und verwendungen davon
WO2016061141A1 (en) 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
MX377591B (es) 2014-10-15 2025-03-10 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas.
KR101787485B1 (ko) * 2015-12-30 2017-11-15 재단법인 의약바이오컨버젼스연구단 재조합 picp 단백질 및 이에 특이적으로 결합하는 항체의 제조방법
JP6937309B2 (ja) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
EP3668985B1 (de) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Verfahren zur reinigung von glykosyliertem protein aus wirtszellen-galectinen und anderen verunreinigungen
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
JP2022520793A (ja) 2019-02-15 2022-04-01 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 自動バイオ製造システム、施設、及びプロセス
EP4370647A1 (de) 2021-07-15 2024-05-22 Just-Evotec Biologics, Inc. Bidirektionales perfusionssystem mit tangentialer strömungsfiltration (tff)
JP2025506122A (ja) 2022-02-10 2025-03-07 アムジエン・インコーポレーテツド ハイスループット配列決定のための抗体タンパク質産物発現コンストラクト
WO2024228717A2 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
CN118580307B (zh) * 2024-05-21 2025-05-27 广东合鸣生物科技有限公司 一种具备紧致抗皱功效的Pro.AH8乙酰基六肽-8及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3582965B2 (ja) 1996-08-23 2004-10-27 株式会社イムノ・ジャパン 哺乳動物細胞用発現ベクター

Also Published As

Publication number Publication date
US7029909B1 (en) 2006-04-18
CA2350226C (en) 2012-04-24
WO2000031284A1 (en) 2000-06-02
EP1132479A4 (de) 2005-08-10
EP1132479A1 (de) 2001-09-12
AU1184000A (en) 2000-06-13
CA2350226A1 (en) 2000-06-02
AU765111B2 (en) 2003-09-11
JP4475814B2 (ja) 2010-06-09
DE69940785D1 (de) 2009-06-04
EP1132479B1 (de) 2009-04-22

Similar Documents

Publication Publication Date Title
ATE429504T1 (de) Proteinexpressionsvektor und benutzung desselbigen
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
BR0113864A (pt) ácidos nucléicos tipo kcp isolados e suas proteìnas codificadas
NO20034959L (no) Anti-frys konsentrat inneholdende fargestoffer C.I. reactive violet 5
DK1007686T3 (da) Tuberkulosevaccine
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
IT1268332B1 (it) Dispositivo manipolatore per la movimentazione, in particolare per l'orientamento di pezzi, utensili, o simili.
DE69934415D1 (de) Neuartiges collectin
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
EA200000567A1 (ru) Бактериальные плазмиды
ATE307940T1 (de) Putzleiste aus kunststoff
ATE186731T1 (de) Anomere fluorribosylamine
IL136496A0 (en) Nucleotide sequences encoding the tomato light hypersensitive phenotype, encoded proteins and uses thereof
DE69731682D1 (de) TAB1 Protein und dafür kodierende DNA
IT1286829B1 (it) Plasmidi contenenti due o piu' competitori disposti in successione e loro uso in tecniche di pcr-competitiva
ITTO20010545A0 (it) Apparecchiatura di controllo dell'iniezione di carburante.
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette
FR2710113B1 (fr) Barreau magnétique courbe ou rectiligne, formé d'aimants disjoints.
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8
Deutsch et al. Erratum: Interaction Physics of the Fast Ignitor Concept [Phys. Rev. Lett. 77, 2483 (1996)]
ITMI920320A1 (it) Composizione marcante-denaturante particolarmente adatta per marcare e denaturare bitumi combustibili o prodotti affini.
ATE409747T1 (de) Mit wt1 interagierendes protein, wtip
Hollander Above the Glass Ceiling
ITTO20010544A0 (it) Apparecchiatura di controllo dell'iniezione di carburante.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties